Mobile website
Archive > Volume 30 Issue 7 > 2023,30(7):541-551. DOI:10.3872/j.issn.1007-385X.2023.07.001 Prev Next
Expert Forum
Therapeutic cancer vaccines: current status and future prospect
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
In recent years, with the in-depth understanding of tumor antigen and mechanism of antitumor immune response, therapeutic cancer vaccines have developed rapidly and are expected to be an important tool for clinical cancer therapy. Meanwhile, breakthroughs in key technologies, such as neo-antigen screening, vaccine design, vaccine delivery system and adjuvant, have further accelerated the development in this field. As for product research and development, many international pharmaceutical companies and emerging biotech companies are laying out various projects of therapeutic cancer vaccines, and several products have been approved for marketing, but the clinical outcomes are not ideal. Although the majority of current therapeutic cancer vaccines are in preclinical and clinical stages, they demonstrate good application prospect and market value. Present review provides an overview of therapeutic cancer vaccines from the perspective of research and development at home and abroad, mainly focusing on the currently fast-growing personalized neo-antigen vaccine, DC-based vaccine and mRNA vaccine. Meanwhile, it also summarizes the current challenges and envisions its to future development, which may provide some clues for research and product development of therapeutic cancer vaccines.
Keywords:
Project Supported:
Clc Number:
